Introduction
The global landscape of oligonucleotide manufacturing companies is rapidly evolving as more developers choose to outsource production to specialized partners. This shift is largely driven by the significant capital investment required for synthesis instruments, analytical platforms, and purification facilities, making collaboration with an experienced oligonucleotide CDMO a more efficient and scalable solution.
We have analyzed over 100 industry participants offering oligonucleotide synthesis services to identify the most competitive players. In this article, we explore the top 10 oligonucleotide manufacturing companies worldwide, covering both domestic and international leaders.
Oligonucleotide manufacturing refers to the chemical synthesis of short DNA or RNA sequences used in research, diagnostics, and therapeutic applications, now increasingly transitioning from lab-scale production to large-scale GMP manufacturing processes.
Market growth is being strongly driven by the rapid expansion of siRNA, ASO, and gene therapy pipelines.
Choosing the right CDMO is critical, as it directly impacts product quality, scalability, regulatory compliance, and overall project success.
Top 10 Global Oligonucleotide Manufacturing Companies
1. Poresyn Solutions
- Website: www.poresyn.com
| Dimension | Description |
|---|---|
| Overview | Headquartered in Xiamen, China, with a USA branch. Covers CPG production and long-chain CDMO. |
| Synthesis Platform | Proprietary Surface Chemistry Architecture Platform for complex long-chain nucleic acids. |
| Solid-Phase Synthesis | Core Innovation: Co-polymer Coated CPG. Nanometer-thick Polystyrene (PS) coating on CPG. |
| Max Length / Throughput | Capable of synthesizing complex 200nt RNA with high crude purity and consistency. |
| Modifications | Universal Modification Ecosystem: Supporting an exhaustive range of linkers, spacers, and custom monomers (including GalNAc, LNA, 2′-MOE, and complex dyes). Our platform is compatible with virtually all commercially available modifications and specialized phosphoramidites, backed by high-performance CPG to ensure superior coupling efficiency even for the most sterically hindered sequences. |
| Purification & Scale | Professional purification; supports research-grade to GMP-level custom synthesis; ISO 9001. |
| Case Study / Summary | Global provider focused on overcoming technical bottlenecks in long fragments. Summary: The innovator in next-gen solid supports and ultra-long RNA synthesis. |
2. Agilent Technologies
- Website: www.agilent.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1999; 18,000+ employees; NYSE listed (A). Major manufacturing sites in Colorado, USA. |
| Synthesis Platform | Premier API manufacturing platform with expanded CDMO capabilities via BioVectra acquisition. |
| Solid-Phase Synthesis | Experts in large-scale flow technology; optimization for large-pore CPG and high-load PS supports. |
| Max Length / Throughput | Focuses on therapeutic oligos (20-30mer); throughput focused on massive single-batch runs. |
| Modifications | Specialized in GalNAc conjugation, 2′-OMe, 2′-MOE, and complex lipid conjugations. |
| Purification & Scale | Industrial-grade column chromatography; 10kg to 100kg+ per batch; full cGMP compliance. |
| Case Study / Summary | Supplier for multiple FDA-approved ASO drugs. Summary: The global benchmark for commercial-scale nucleic acid API. |
3. Merck KGaA
- Website: www.sigmaaldrich.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1668; 64,000+ employees; Frankfurt listed. Global bases including USA, Germany, and Singapore. |
| Synthesis Platform | Centered around Sigma-Aldrich; provides end-to-end services from R&D to GMP. |
| Solid-Phase Synthesis | Proprietary Controlled Pore Glass (CPG) processes to ensure high coupling efficiency at all scales. |
| Max Length / Throughput | Supports long fragments up to 300mer; strong plate-based HTP lines for the NGS market. |
| Modifications | Comprehensive library: quenchers, fluorophores, LNA, and specialized linkers. |
| Purification & Scale | HPLC, PAGE, RP-OPC; scales from nmol to kg; GMP/ISO diagnostic-grade materials. |
| Case Study / Summary | #1 market share in research-grade oligos. Summary: The global gold standard for research and diagnostic oligonucleotides. |
4. Integrated DNA Technologies (IDT)
- Website: www.idtdna.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1987 (Danaher); thousands of employees. Hubs in USA, Belgium, and Singapore. |
| Synthesis Platform | Proprietary synthesizer and reagent systems; world’s largest custom oligo provider. |
| Solid-Phase Synthesis | Ultramer™ technology uses unique support modifications to reduce deletion mutations in long chains. |
| Max Length / Throughput | Leading synthesis for 200-350mer; world-class automated high-throughput order processing. |
| Modifications | Features Affinity Plus™ (LNA-like), dual-labeled probes, and CRISPR-specific guide RNAs. |
| Purification & Scale | High-precision HPLC and PAGE; scales from nmol to 10g+ batch production. |
| Case Study / Summary | Preferred supplier for NGS labs worldwide. Summary: The industry leader in custom synthesis and long-fragment technology. |
5. Lonza
- Website: www.lonza.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1897; HQ in Switzerland; 18,000+ employees. Major sites in Visp, UK, and USA. |
| Synthesis Platform | Top-tier global CDMO from nucleic acid API synthesis to LNP encapsulation. |
| Solid-Phase Synthesis | Focuses on carrier fluid dynamics in large reactors with mixed-matrix support applications. |
| Max Length / Throughput | Focused on clinical-grade therapeutic oligos (20-80mer); high-throughput GMP manufacturing. |
| Modifications | Specialized in Conjugation: ADC-Oligo, GalNAc delivery systems, and lipid-based targeting. |
| Purification & Scale | Industrial Prep-HPLC; production scales of 10kg to 100kg; fully FDA/EMA GMP compliant. |
| Case Study / Summary | Supports numerous RNAi and mRNA projects in IND/NDA stages. Summary: The versatile CDMO giant for nucleic acid clinical translation. |
6. Bachem
- Website: www.bachem.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1971; SIX listed; ~2,000 employees. Bases in Switzerland and the USA. |
| Synthesis Platform | Leveraging solid-phase mastery from peptide manufacturing for oligonucleotide production. |
| Solid-Phase Synthesis | Innovation in green chemistry and pushing resin loading limits for large-scale batches. |
| Max Length / Throughput | Focused on therapeutic oligos; capacity expanding toward Metric Ton levels. |
| Modifications | Expert in Phosphorothioate (PS) stereochemistry and complex multi-conjugations. |
| Purification & Scale | Massive HPLC purification columns; Multi-kg production; full cGMP validation. |
| Case Study / Summary | Secured multiple long-term commercial supply contracts. Summary: Tonnage-scale nucleic acid experts built on peptide heritage. |
7. Eurofins Genomics
- Website: www.eurofinsgenomics.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1987; Part of Eurofins Scientific (SXX listed); ~62,000 employees globally. Hubs in Germany, USA, and Japan. |
| Synthesis Platform | Comprehensive “Lab-to-Clinic” platform; seamless transition from high-throughput RUO oligos to large-scale therapeutic GMP production. |
| Solid-Phase Synthesis | Specialized in high-efficiency synthesis cycles using proprietary phosphoramidite chemistry and optimized CPG/resin supports for long-chain oligos. |
| Max Length / Throughput | Capable of synthesizing long-mer oligonucleotides (100nt+); Massive throughput with automated synthesis lines for diagnostic and therapeutic leads. |
| Modifications | Extensive library of 300+ modifications including LNA, 2′-MOE, GalNAc conjugation, and various fluorophore/quencher combinations. |
| Purification & Scale | Advanced purification via HPLC, PAGE, and AX-HPLC; scaled from nmol for screening to multi-gram/kg batches for clinical trials; ISO & cGMP certified. |
| Case Study / Summary | Key supplier for global IVD companies and mRNA vaccine developers. Summary: A global powerhouse offering unmatched scalability and a robust Western-based supply chain. |
8. ST Pharm
- Website: www.stpharm.co.kr
| Dimension | Description |
|---|---|
| Overview | Leading South Korean CDMO; part of Dong-A Socio Group. Bases in Ansan and Sihwa, KR. |
| Synthesis Platform | One of the world’s top 3 nucleic acid API producers by volume. |
| Solid-Phase Synthesis | Focused on Vertical Integration from Monomer to Oligo for rigorous support batch control. |
| Max Length / Throughput | Expanding capacity from 4mmol to 14mol (2026 target); supports massive batch output. |
| Modifications | Strong in 2′-OMe, 2′-F, 2′-MOE, and LNA for bulk raw material supply. |
| Purification & Scale | Industrial-scale purification; supports IND/NDA and commercial production; FDA/EMA audited. |
| Case Study / Summary | Designated supplier for several global Phase III oligo drugs. Summary: Asia’s leader in nucleic acid API manufacturing scale. |
9. Kaneka Eurogentec
- Website: www.eurogentec.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1985 (Kaneka Group); ~400 employees. Bases in Belgium and the USA. |
| Synthesis Platform | Leading European producer for oligos and peptides with a strong diagnostic focus. |
| Solid-Phase Synthesis | 40+ years experience; excels in specific CPG supports for 3′ modifications. |
| Max Length / Throughput | Supports synthesis from 2 to 225 bases; flexible transition from research to clinical. |
| Modifications | Over 300 modifications; expertise in PNA (Peptide Nucleic Acids) and fluorescent tags. |
| Purification & Scale | HPLC/PAGE purification; mg to gram scale; ISO 13485 & GMP compliant. |
| Case Study / Summary | Established supplier for European IVD and vaccine components. Summary: Europe’s boutique provider for custom GMP synthesis. |
10. Thermo Fisher Scientific
- Website: www.thermofisher.com
| Dimension | Description |
|---|---|
| Overview | Founded in 1956; 120,000+ employees; NYSE listed (TMO). Global sites in the USA, Europe, and China. |
| Synthesis Platform | Vertically integrated platform from reagents to Applied Biosystems™ synthesizers. |
| Solid-Phase Synthesis | Uses optimized High-quality CPG supports with strict reagent purity control. |
| Max Length / Throughput | Supports 100mer+ standard; Ultramer™ technology reaches 200nt. High-throughput parallel synthesis. |
| Modifications | Over 200 modifications including Phosphorothioate (PS), LNA, and non-natural bases. |
| Purification & Scale | HPLC, PAGE, and desalt; mg to kg scale; compliant with ISO 13485 / GMP. |
| Case Study / Summary | Major supplier for global IVD and mRNA raw materials. Summary: The titan of the global life sciences supply chain. |
Comparative Analysis of Top 10 Oligo Manufacturing Companies
| Company | Primary Strength | Scale Capability | Technical Edge | Target Market |
| Thermo Fisher | Supply Chain Titan | RUO to Large GMP | Integrated platform; Ultramer™ (200nt) | Global IVD & mRNA |
| Agilent | Commercial API | 10kg to 100kg+ | Large-scale flow tech; GalNAc expert | FDA-approved ASO drugs |
| Merck KGaA | Research Standard | nmol to kg | 300mer capability; Proprietary CPG | Global R&D & Diagnostics |
| IDT (Danaher) | Custom Synthesis | nmol to 10g+ | Ultramer™ & CRISPR guide RNA leader | NGS & Academic labs |
| Lonza | Clinical CDMO | 10kg to 100kg | LNP encapsulation; ADC-Oligo | RNAi & mRNA Clinical trials |
| Bachem | Tonnage Scale | Multi-kg to Ton | Green chemistry; PS stereochemistry | Commercial Therapeutic Oligos |
| Eurofins | Lab-to-Clinic | nmol to kg | 300+ modification library | Global IVD & Vaccine Dev |
| ST Pharm | Asia’s API Leader | 4mmol to 14mol | Vertical integration (Monomer to Oligo) | Global Phase III & Commercial |
| Kaneka Eurogentec | European Boutique | mg to gram | PNA (Peptide Nucleic Acids) expertise | European IVD & Clinical |
| Poresyn Solutions | Support Innovation | Research to GMP | PS-coated CPG; Ultra-long RNA (200nt) | Complex/Long-chain Bottlenecks |
Key Trends in Oligonucleotide Manufacturing: Navigating the New Frontier
The landscape of oligonucleotide synthesis is shifting from small-scale research tools to a high-stakes clinical and commercial drug platform. As RNA therapies evolve from “pandemic-driven” solutions to long-term chronic disease platforms, the industry is witnessing three pivotal trends:
1. The Ascent of Long Oligonucleotides (>100 nt): Meeting Complex Disease Needs
The next major wave in biotechnology is the demand for significantly longer and more complex sequences. To tackle intricate genetic diseases, researchers are pushing beyond standard primers toward Long Oligonucleosides (>100 nt).
- Big Pharma Strategic Layout: Global giants such as Novartis, Johnson & Johnson, and Roche are aggressively expanding their pipelines in long-chain synthesis for CRISPR, mRNA, and advanced RNAi applications.
- Technical Bottlenecks: While mid-to-long chains are the clear future, the industry still struggles with exponential drops in coupling efficiency, low crude purity, and insufficient OD (Optical Density) values. Achieving industrial-scale production of high-quality long chains remains a primary competitive barrier.
2. The GMP Imperative: From Lab Bench to Commercial Scale
The “Gold Rush” in the oligo sector is evidenced by the massive surge in Oligo CDMO market growth (CAGR 15%–20%+). With the explosion of siRNA, ASO, and mRNA pipelines, regulatory compliance is now the baseline for success.
- The Scarcity of Scale: While small-scale synthesis is saturated, there is an extreme global shortage of mid-to-large scale (100g to multi-kg) GMP manufacturing capacity.
- High Entry Barriers: Obtaining and maintaining a GMP license is an 8-figure investment in infrastructure and quality systems. Today, GMP manufacturing accounts for over 60% of the total CDMO market share, reflecting a shift where “clinical readiness” is the most valued currency.
3. High-End Modifications & Delivery: The True Differentiators
The gap between standard oligo houses and elite manufacturers is widening in the realm of complex chemical modifications. We are moving toward a “Sequence + Delivery” integrated design rather than separate modules.
- High-Affinity Nucleoside Modifications: The use of LNA (Locked Nucleic Acid) and cEt (Constrained Ethyl) has become critical. However, high monomer costs and extreme sensitivity to cycle efficiency require near-perfect synthesis protocols.
- Delivery System Conjugation:
- GalNAc (Liver Targeting): Now the mainstream standard for liver-directed therapies.
- Lipid & Cholesterol Conjugates: Essential for extra-hepatic delivery.
- PEGylation: Gaining traction in specific long-circulating applications.
- Integrated Design: Modern drug development treats the delivery ligand and the oligo sequence as a single molecular entity, demanding that manufacturers possess both advanced chemistry and robust conjugation capabilities.
Summary: The future of the industry belongs to those who can master the “Long-Chain + High-End Modification + GMP Scale-up” trifecta. Innovative platforms like Poresyn Solutions, with its PS-coated CPG technology, are specifically designed to address these industrial bottlenecks.
FAQ
1. What is oligonucleotide manufacturing?
Oligonucleotide manufacturing is the chemical synthesis of short DNA or RNA sequences used in research, diagnostics, and therapeutic applications.
2. Which companies produce siRNA at scale?
Leading oligonucleotide manufacturing companies such as Lonza, WuXi AppTec, ST Pharm, and Nitto Avecia offer large-scale siRNA production.
3. What is the difference between DNA and RNA synthesis?
DNA synthesis typically uses standard phosphoramidite chemistry, while RNA synthesis is more complex due to the reactive 2′-OH group, requiring additional protection and deprotection steps.
4. What are the main applications of oligonucleotide synthesis?
Oligonucleotides are widely used in PCR, gene editing, molecular diagnostics, and therapeutic areas such as ASO and siRNA drugs.
5. What is the typical scale of oligonucleotide manufacturing?
Production scales range from research-level (milligram) to clinical and commercial-scale GMP manufacturing (multi-kilogram).
6. What factors affect oligonucleotide synthesis efficiency?
Key factors include sequence length, modification complexity, coupling efficiency, purification strategy, and the quality of solid supports such as CPG.
7. Why are long oligonucleotides (>100 nt) challenging to produce?
Because each synthesis cycle has a small loss, longer sequences accumulate errors, resulting in lower yield and higher impurity levels.
8. What types of modifications are commonly used in oligonucleotides?
Common modifications include 2’-OMe, phosphorothioate (PS), and LNA, which enhance stability, binding affinity, and therapeutic performance.
9. How can you verify if a company truly has a GMP license?
You should request official GMP certificates issued by recognized regulatory authorities (such as FDA, EMA, or NMPA), check inspection records, and verify whether the facility has passed recent audits. On-site audits or third-party inspections are the most reliable way to confirm real GMP compliance rather than just marketing claims.
10. What is the difference between GMP and GLP?
GMP (Good Manufacturing Practice) focuses on ensuring consistent product quality and compliance during manufacturing, especially for clinical and commercial production, while GLP (Good Laboratory Practice) applies to non-clinical laboratory studies and ensures the integrity and reliability of research data.
11. How to evaluate the real quality capability of a biotech company, especially in China?
Key indicators include whether the company has strong core technical capabilities, such as experience with long-chain or modified oligonucleotides; conducting on-site evaluations of equipment (e.g., synthesis platforms and chromatography systems, including brand and performance level); and assessing team strength, such as the proportion of PhD-level scientists or senior experts. These factors provide a more accurate picture than marketing materials alone.
12. How to choose a reliable oligonucleotide manufacturing company in China?
Focus on companies with proven GMP experience, advanced equipment, strong technical teams, and successful case studies in complex oligonucleotide synthesis. Prioritize those with transparent processes, scalable production capabilities, and demonstrated consistency in quality and delivery.
